Regeneron Pharmaceuticals (REGN) 13F Filings: Institutional Buyers & Sellers (Q2 2026)

REGN ranks #292 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

1354 institutions disclose a position in REGN, but none treat it as a major bet — even Dodge & Cox, its most concentrated holder, allocates just 1.6% of its own portfolio to it.

Fjarde Ap-fonden /fourth Swedish National Pension Fund has added to its REGN position for two straight quarters, increasing it by $6.7M to reach $30.4M today.

Assenagon Asset Management S.A. has trimmed its REGN position for two straight quarters, cutting it by $132.6M while still holding $28.0M.

REGN is down 0.7% today, but institutions show net buying of $31.7B this quarter — a divergence between today's price move and the underlying institutional flow.

REGN posted net income of $4.3B over the trailing twelve months, and currently trades at a P/E of 19.8.

• Profitable — net income of $4.3B over the trailing twelve months
• Revenue grew 9.3% year over year
• Net income declined year over year, from $4.5B to $4.3B
• Generated $5.0B in positive operating cash flow
• Current ratio of 4.13x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.30x equity — within a conventional range